Abstract 6073
Background
Thyroid carcinomas are fairly uncommon tumors. They include disease types that range from indolent behavior such as papillary carcinomas to the fulminant and lethal anaplastic disease. The aim of this study was to analyze the characteristics of patients diagnosed with thyroid carcinoma in the United States between 2000 till 2016.
Methods
This study was conducted using SEER*Stat version 8.3.5 to analyze clinical and pathological characteristics of thyroid carcinoma patients diagnosed in the period between 2000 and 2016 in the United States through exploiting the data obtained from SEER Regs Research Data Nov 2018. The data were statistically analyzed using SPSS version 20.
Results
A total of 172525 cases of thyroid carcinoma were diagnosed. The median age at diagnosis was 50 years. Females were the most common gender affected (n = 131059; 75.7%). The incidence rate of thyroid carcinoma was estimated to be 12 per 100,000 cases. Papillary adenocarcinoma, NOS was the most common histology (n = 84323; 48.7%), followed by follicular variant of papillary carcinoma (n = 46830, 27.1%). The disease was the only primary tumor in most of cases (n = 139831; 80.8%). The majority of patients had localized early disease at the time of diagnosis (Stage I = 89235; 51.5%), and surgery was performed in the vast majority of case (n = 164742; 95.2%). The median survival wasn’t reached, with observed survival, at 5 and 10 years, was 94.2% & 89.2% respectively and relative survival at 5 and 10 years was 98% & 97.4%, respectively.
Conclusions
Thyroid carcinoma is a disease of middle ages, mainly, with female predominance. Papillary thyroid carcinoma is the most common histology and most of patients tend to present at early stage. The survival is good with median survival wasn’t reached and relative 5- year and 10- year survival of 98% & 97.4%, respectively.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3330 - Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy
Presenter: Leonora De Boo
Session: Poster Display session 2
Resources:
Abstract
3971 - Unravelling the biological characteristics of MammaPrint extreme risk subgroups
Presenter: Rajith Bhaskaran
Session: Poster Display session 2
Resources:
Abstract
5871 - Residual Cancer burden as a prognostic factor in a large series of Neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes
Presenter: Catalina Falo
Session: Poster Display session 2
Resources:
Abstract
5014 - Clinical validation of CanAssist Breast in a Spanish cohort
Presenter: Manjiri Bakre
Session: Poster Display session 2
Resources:
Abstract
2787 - Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer
Presenter: Peter A. Fasching
Session: Poster Display session 2
Resources:
Abstract
4301 - Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial
Presenter: Gaia Griguolo
Session: Poster Display session 2
Resources:
Abstract
3205 - Frequency of germline mutations in women's cancer susceptibility genes in a large cohort of Chinese breast cancer patients
Presenter: Ning Liao
Session: Poster Display session 2
Resources:
Abstract
4091 - Triple blinded Prospective Study assessing the Impact of Genomics & Artificial Intelligence Watson For Oncology (WFO) on MDT’s Decision of Adjuvant Systemic Therapy for Hormone Receptor Positive Early Breast Carcinoma-
Presenter: Somashekhar Sampige Prasannakumar
Session: Poster Display session 2
Resources:
Abstract
4359 - Prognostic significance of Progesterone Receptor levels in luminal-like Her2- early Breast Cancer patients. A retrospective single Cancer Center analysis.
Presenter: Anna Diana
Session: Poster Display session 2
Resources:
Abstract
1369 - PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a meta-analysis
Presenter: Francesco Schettini
Session: Poster Display session 2
Resources:
Abstract